Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human trial evaluating EBC-129 in patients with solid tumours

Next Previous
Trial Profile

A first-in-human trial evaluating EBC-129 in patients with solid tumours

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EBC-129 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man

Most Recent Events

  • 08 Mar 2023 According to a WuXi media release, company receives FDA clearance of IND Application to begin this trial with the support of company's partners; Experimental Drug Development Centre (EDDC), Singapore national drug discovery and development platform hosted by Agency for Science, Technology and Research (A*STAR) and its collaborators.
  • 05 Feb 2023 New trial record
  • 06 Jan 2023 According to an A STAR media release, approval has been obtained from the U.S. Food and Drug Administration (FDA) to conduct this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top